CL
Core Laboratories
CLB · NYSE
$12.50 -0.24% (-$0.03)
1M +0.40%
Market Cap $577.1M
P/E Ratio 23.70x
Div. Yield 0.32%
ROE 9.03%
Bulios Fair Price
$11.47
8.2% downside
Current Price
$12.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CLB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
36 /100
Fair P/E 23.70x
EV/EBITDA 11.48x
P/FCF 53.78x
Growth
79 /100
Growing EPS growth 17.42%
Rev. growth 2.44%
Book val. growth 14.94%
Profitability
49 /100
Moderate Gross margin 18.12%
Net margin 4.69%
FCF margin 2.07%
Quality
61 /100
Average ROIC 6.48%
ROE 9.03%
Asset turnover 0.88x
Debt
78 /100
Low Debt/Equity 0.61x
Current ratio 2.12x
Net debt/EBITDA 2.27x
Stability
90 /100
Stable Beta 1.08x
Rev. volatility 1.81%
Profitable years 5
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CLB
Online
Sector
Energy
Industry
Oil & Gas Equipment & Services
CEO
Lawrence V. Bruno
Employees
3,300
Headquarters
Houston
Upcoming events
28 OCT
Earnings
Upcoming earnings report